相关临床试验
176
21 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1811
进行中（未招募）
11
6.3%
已完成
101
57.4%
Enrolling By Invitation
3
1.7%
尚未招募
7
4.0%
招募中
15
8.5%
终止
4
2.3%
Unknown
32
18.2%
撤回
3
1.7%
暂无批准数据
- Researchers from the University of Oslo and Oslo University Hospital discovered that the placenta selectively transports IgG antibodies while largely excluding albumin, despite both binding the neonatal Fc receptor (FcRn). - The study, published in Science Immunology, shows that fusing albumin to therapeutic IgG antibodies yields biologics with long plasma half-life and substantially reduced placental transport. - An engineered albumin variant (QMP) with optimized FcRn binding further reduced fetal exposure, validated in a mouse model of fetal and neonatal alloimmune thrombocytopenia (FNAIT). - The findings offer a platform to design a new generation of biologic medicines that combine long-lasting efficacy with improved safety during pregnancy.
- A study published in Nature Immunology demonstrates that T cells engineered with TCRs from healthy donors can target a shared β-catenin mutation to eradicate solid tumors. - The research, led by PhD candidate Maria Stadheim Eggebø and Professor Johanna Olweus, won the OUS award for outstanding research articles published in fall 2025. - Mutations specific to cancer cells form unique peptides recognized by T-cell receptors, but patients' own T cells often fail to recognize these neoantigens. - Healthy donor-derived T cells show superior ability to recognize cancer-specific mutations, offering a promising new immunotherapy strategy for lung and prostate cancers.
- A comprehensive Norwegian population study of 26,210 pregnancies found no increased risk of neurodevelopmental disorders, including autism and ADHD, in children whose mothers used triptans for migraine treatment during pregnancy. - The study followed children for up to 14 years and found that 2.2% of children in the highest triptan exposure group developed ADHD compared to 2.1% in the non-medicated group, with similar minimal differences for other disorders. - These findings provide reassuring safety data for the nearly 20% of childbearing-age women who suffer from migraine, particularly those who may unknowingly take triptans in early pregnancy. - The research addresses a critical clinical need, as approximately 8% of pregnant women experience worsening migraine attacks that can lead to maternal and fetal complications if left untreated.
